
Opinion|Videos|January 28, 2025
Overview of the inMIND Study
Panelists discuss the inMIND study, exploring the efficacy and safety of mindetuximab for the treatment of relapsed or refractory non-Hodgkin lymphoma and its potential impact on future therapeutic strategies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















